Sjögren's syndrome. Lancet, pp.23-29, 2005. ,
Pathogenesis of Sj??gren??s syndrome and therapeutic consequences, Current Opinion in Rheumatology, vol.22, issue.5, pp.471-478, 2010. ,
DOI : 10.1097/BOR.0b013e32833c36c5
Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors, Annals of the Rheumatic Diseases, vol.65, issue.6, pp.796-803, 2006. ,
DOI : 10.1136/ard.2005.041186
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj??gren's syndrome, Arthritis & Rheumatism, vol.39, issue.series B, pp.741-748, 2002. ,
DOI : 10.1002/art.10221
Increased Risk of Lymphoma in Sicca Syndrome, Annals of Internal Medicine, vol.89, issue.6, pp.888-92, 1978. ,
DOI : 10.7326/0003-4819-89-6-888
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.1103-1112, 2010. ,
DOI : 10.1136/ard.2009.110619
An important role for B-cell activation factor and B cells in the pathogenesis of Sj??gren??s syndrome, Current Opinion in Rheumatology, vol.19, issue.5, pp.406-419, 2007. ,
DOI : 10.1097/BOR.0b013e328277ef4c
Association Between Circulating Levels of the Novel TNF Family Members APRIL and BAFF and Lymphoid Organization in Primary Sj??gren???s Syndrome, Journal of Clinical Immunology, vol.59, issue.3, pp.189-201, 2005. ,
DOI : 10.1007/s10875-005-4091-5
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.62, issue.2, pp.168-71, 2003. ,
DOI : 10.1136/ard.62.2.168
B-cell Activating Factor of the Tumour Necrosis Factor Family Expression in Blood Monocytes and T Cells from Patients with Primary Sj??gren???s Syndrome, Scandinavian Journal of Immunology, vol.201, issue.2, pp.185-92, 2008. ,
DOI : 10.1111/j.1365-3083.2007.02049.x
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome, Arthritis Rheum, vol.56, pp.1464-77, 2007. ,
Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus, Annals of the Rheumatic Diseases, vol.66, issue.6, pp.790-797, 2007. ,
DOI : 10.1136/ard.2006.065656
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome, Blood, vol.104, issue.8, pp.2247-53, 2004. ,
DOI : 10.1182/blood-2004-02-0762
Correlation of serum B lymphocyte stimulator and ??2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.64, issue.7, p.1050, 2005. ,
DOI : 10.1136/ard.2004.030643
Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.66, issue.1, pp.23-30, 2007. ,
DOI : 10.1136/ard.2006.052159
Microglobulin and Lymphocytic Infiltration in Sj??gren's Syndrome, New England Journal of Medicine, vol.293, issue.24, pp.1228-1259, 1975. ,
DOI : 10.1056/NEJM197512112932404
High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome, J Immunol, vol.130, pp.2663-2668, 1983. ,
Serum ??2 microglobulin correlates with the new ESSDAI in patients with Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.70, issue.12, pp.2236-2237, 2011. ,
DOI : 10.1136/ard.2011.153098
BLyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands, 2012. ,
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.968-72, 2011. ,
DOI : 10.1136/ard.2010.143743
Unexplained Opportunistic Infections and CD4+ T-Lymphocytopenia without HIV Infection -- An Investigation of Cases in the United States, New England Journal of Medicine, vol.328, issue.6, pp.373-379, 1993. ,
DOI : 10.1056/NEJM199302113280601
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse, Arthritis & Rheumatism, vol.174, issue.3, pp.723-755, 2006. ,
DOI : 10.1002/art.21650
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production, Annals of the Rheumatic Diseases, vol.66, issue.5, pp.700-703, 2007. ,
DOI : 10.1136/ard.2006.060772
Mucosa-Associated Lymphoid Tissue Lymphoma in Sj??gren's Syndrome: Risks, Management, and Prognosis, Rheumatic Disease Clinics of North America, vol.34, issue.4, pp.921-954, 2008. ,
DOI : 10.1016/j.rdc.2008.08.006
Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sj??gren's syndrome, Arthritis & Rheumatism, vol.36, issue.5, pp.767-72, 1996. ,
DOI : 10.1002/art.1780390508
Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors, Annals of the Rheumatic Diseases, vol.65, issue.6, pp.796-803, 2006. ,
DOI : 10.1136/ard.2005.041186
Primary Sjogren???s Syndrome: Time for Prospective Cohorts, Current Pharmaceutical Biotechnology, vol.13, issue.10, pp.2022-2027, 2012. ,
DOI : 10.2174/138920112802273128
In primary Sj??gren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response, Arthritis & Rheumatism, vol.20, issue.8, pp.2240-2245, 2003. ,
DOI : 10.1002/art.11103
Quantitative assessment of antibodies to ribonucleoproteins in primary Sjogren syndrome: correlation with B-cell biomarkers and disease activity, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1208-1220, 2009. ,
DOI : 10.1136/ard.2008.095257
No evidence for an association between the 2871 T/C promoter polymorphism in the B-cellactivating factor gene and primary Sjögren's syndrome, Arthritis Research & Therapy, vol.8, issue.1, p.30, 2006. ,
DOI : 10.1186/ar1884
Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome, Rheumatology, vol.47, issue.9, pp.1311-1316, 2008. ,
DOI : 10.1093/rheumatology/ken246
Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fc?? receptors, Arthritis & Rheumatism, vol.1107, issue.5, pp.1446-51, 2011. ,
DOI : 10.1002/art.30274
Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma, Cancer Research, vol.69, issue.10, pp.4217-4241, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-4915
Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders, Journal of Clinical Oncology, vol.24, issue.6, pp.983-990, 2006. ,
DOI : 10.1200/JCO.2005.02.7938
High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura, British Journal of Haematology, vol.166, issue.2, pp.309-310, 2007. ,
DOI : 10.1126/science.1061965